bernie sanders novo nordisk news - Search News

Novo Nordisk faces US Senate committee

CNBC on MSN · 1h

Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices

Novo Nordisk's top executive is slated to face a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaard Jørgensen,

Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing

U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,

Barron's on MSN · 1d

Novo CEO Faces Sanders Over GLP-1 Drug Prices. All of Pharma Should Tune In.

A Senate hearing Tuesday will look at why the list prices of Ozempic and Wegovy are much higher in the U.S. than in comparable countries.

Novo CEO, Sanders to Face Off Over US Prices for Ozempic and Wegovy

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

14h

Novo CEO to blame drug middlemen

The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

1d

Bernie Sanders Questions Why Your Monthly Ozempic Prescription Costs More Than A Luxury Handbag When It Can Be Sold For Less Than $100

Ozempic is a popular diabetes drug that is also used for weight loss by suppressing appetite. Sanders expressed confidence ...

Bernie Sanders keeps the heat on Novo’s high prices

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

16h

Novo CEO Blames Ozempic’s High Cost on Drug Middlemen’s Tactics

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...

5don MSN

Sanders says generic drugmakers could sell Novo Nordisk Ozempic for less than $100

Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results